AbbVie's Rinvoq Becomes First Oral JAK Inhibitor Approved for Giant Cell Arteritis as Novartis' Cosentyx Fails Phase III Trial
Key Insights
AbbVie (search)'s Rinvoq (upadacitinib) received FDA approval in April 2025 as the first oral JAK inhibitor for adult giant cell arteritis (search) patients, based on Phase III SELECT-GCA trial results showing 46.4% sustained remission versus 29% placebo.
Novartis' Cosentyx (secukinumab) failed to meet its primary endpoint in the Phase III GCAptAIN trial in July 2025, showing no significant improvement in sustained remission at 52 weeks compared to placebo.
Over six pharmaceutical companies are actively developing more than six therapeutic candidates for giant cell arteritis (search), the most common vasculitis (search) in individuals over 50 that can cause permanent vision loss without treatment.
AbbVie (search) achieved a significant regulatory milestone in April 2025 when its oral JAK inhibitor Rinvoq (upadacitinib) became the first drug in its class approved by the FDA for treating adult patients with giant cell arteritis (search) (GCA). The approval was based on results from the Phase III SELECT-GCA trial, where 46.4% of patients receiving 15 mg daily with a steroid taper achieved sustained remission between weeks 12 and 52, compared to 29% in the placebo group (p = 0.002).
This breakthrough comes as the GCA therapeutic landscape experiences both successes and setbacks. In July 2025, Novartis' Cosentyx (secukinumab) failed to meet its primary endpoint in the Phase III GCAptAIN trial, showing no significant improvement in sustained remission at 52 weeks compared to placebo. Although there were reductions in steroid use, these differences were not statistically significant.
Growing Pipeline Addresses Critical Unmet Need
Giant cell arteritis (search) represents the most common type of vasculitis (search) in individuals over 50, characterized by inflammation of medium and large arteries. The condition affects temporal and other cranial arteries in cranial GCA, while large-vessel GCA involves the aorta and other major vessels. Without timely diagnosis and treatment, GCA can cause serious complications, including sudden and permanent vision loss.
DelveInsight reports that more than six pharmaceutical and biotech companies are actively advancing over six therapeutic candidates targeting GCA. These candidates are in various stages of preclinical and clinical development, reflecting significant innovation in addressing this critical public health challenge.
Diverse Therapeutic Approaches Under Investigation
The current pipeline includes multiple mechanisms of action and delivery routes. Key companies developing new therapies include Novartis, AbbVie (search), XOMA, Kiniksa Pharmaceuticals, Eli Lilly, Janssen Biotech (search), and Dr. Reddy's Laboratories.
Secukinumab, a fully human monoclonal antibody that specifically targets interleukin-17A (search) (IL-17A), represents one approach to reducing inflammation in GCA. The therapy, already approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, was being evaluated in Phase III trials for GCA before its recent setback.
Upadacitinib takes a different approach as an oral, selective Janus kinase 1 (JAK1 (search)) inhibitor. Originally approved in August 2019 for multiple inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis, the drug has now expanded its indication to include GCA.
Clinical Presentation and Current Treatment Challenges
When cranial arteries are involved, patients may experience unilateral or occipital headaches, jaw pain while chewing (jaw claudication), scalp tenderness, arm discomfort, visual disturbances such as double vision, and noticeable, tender swelling of the temporal artery. Systemic symptoms, more common in large-vessel GCA, can include fever, weight loss, loss of appetite, and polymyalgia.
GCA is closely associated with polymyalgia rheumatica (search) (PMR), with approximately 40-60% of GCA patients also having PMR, and 15-20% of PMR patients potentially developing GCA. Treatment typically involves corticosteroids to relieve symptoms and prevent recurrence, often combined with immunosuppressive therapies to regulate the immune response.
Pipeline Diversity Reflects Innovation
The therapeutic pipeline spans multiple development stages, from late-stage Phase III products to early discovery candidates. Pipeline assessment reveals diversity in product types including monotherapies and combination approaches, with various routes of administration including oral, parenteral, intravenous, subcutaneous, and topical formulations.
Molecule types under investigation include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy approaches. This diversity reflects the complex pathophysiology of GCA and the multiple potential intervention points in the inflammatory cascade.
As GCA becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes (search), cardiovascular disease (search), and certain cancers, the demand for safer and more effective treatments continues to grow. The recent approval of Rinvoq represents a significant advancement in providing oral treatment options for patients, while the continued pipeline development suggests additional therapeutic options may emerge in the coming years.